• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Development of high-throughput liquid chips for respiratory virus detection

tetano

Editor, Senior Moderator
Clin Lab. 2014;60(3):347-61.
Development of high-throughput liquid chips for respiratory virus detection.
Xiaoyan L, Jinying C, Mei K, Xu S, Ming Z, Liru G.
Abstract
BACKGROUND:

Diagnosis of viral respiratory tract infections clinically is often nonspecific, and a rapid, high-throughput laboratory technique which can detect major respiratory viruses is desirable.
METHODS:

Two liquid chip panels were developed which used a target-enriched multiplexed RT-PCR amplification followed by Luminex liquid chip hybridization based on xMAP technology. One was for the detection of 5 type/ subtypes of the influenza virus (called Influenza Panel), the other was for the identification of 14 major respiratory viruses, including emerging human metapneumovirus (HMPV), coronavirus (CoV NL63, HKU1), human bocavirus (HBoV), and WU polyomavirus (WUPyV) (called Respiratory Panel). The analytical sensitivity and specificity of these two panels were determined. 108 throat swabs from influenza-like-illness (ILI) cases and 88 nasopharyngeal aspirates (NPA) from hospitalized children with lower respiratory tract infections (LRTI) were used to evaluate the two panels.
RESULTS:

The Influenza Panel returned the analytical sensitivity of 4 - 10 copies vRNA/microL of sample for seasonal H1N1, H3N2, pandemic H1N1, and B, and 200 copies vRNA/microL of sample for H5. The analytical sensitivity of the Respiratory Panel was as follows: 10 - 150 copies vRNA/microL of sample for most of the viral targets tested in this panel except RSV (400 copies vRNA/microL of sample). No cross reactivity was observed for both panels. As determined by commercial multi-PCR kit and conventional PCR (for HBoV and WUPyV), the diagnostic sensitivity of the Respiratory Panel for each viral targets ranged from 50.0% to 100.0%, the diagnostic specificity was 96.2%-100.0%, and accordance rate was 93.2% - 100.0%, the kappa correlation of eight viral targets was > 0.75.
CONCLUSIONS:

Two liquid chip assay panels, developed based on xMAP technology, can detect 5 types/subtypes of influenza viruses and 14 respiratory viruses simultaneously in one reaction in 6 hours. They are potentially rapid, sensitive, specific, and high throughput diagnostic tools for major viral pathogens associated with respiratory tract infection.

PMID:
24697109
[PubMed - in process]

http://www.ncbi.nlm.nih.gov/pubmed/24697109
 
Back
Top Bottom